Abstract
Chronic hepatitis B virus infection (HBV) continues to pose a serious global health threat in many areas of the world, particularly in sub-Saharan Africa, the Western Pacific Region and areas of Eastern Europe. Endemicity is heterogeneous within and across regions owing to variable implementation of childhood and birth-dose vaccination programs, inconsistent screening of blood products, injection drug use, and poor education initiatives. This review aims to provide comprehensive up-to-date estimates of global seroprevalence of chronic HBV across six World Health Organization (WHO) regions, noting patterns of change over time and highlighting potential region-specific barriers to the diagnosis and elimination of HBV.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call